Advertisement

Journal of Endocrinological Investigation

, Volume 39, Issue 8, pp 917–922 | Cite as

The relationship between visfatin and serum concentrations of C-reactive protein, interleukin 6 in patients with metabolic syndrome

  • M. J. Hosseinzadeh-AttarEmail author
  • A. Golpaie
  • M. Foroughi
  • F. Hosseinpanah
  • S. Zahediasl
  • F. Azizi
Original Article

Abstract

Aim

To evaluate the relationship between inflammatory and pro inflammatory markers, with obesity and visceral adiposity in male subjects with or without metabolic syndrome (MS).

Subjects and methods

A total of 37 patients with MS and 37 age matched controls were included (mean age 46.35 ± 1.6 years). MS was defined by the criteria of the international diabetes federation 2005. Anthropometric and biochemical profiles, including high-sensitivity C-reactive protein (Hs-CRP), visfatin and interleukin 6 (IL-6), were measured. Data were compared between groups by using t test. Pearson’s correlation was used to evaluate the relationship between variables. P values less than 0.05 were considered as statistically significant.

Results

In patients with MS, CRP and IL-6 were significantly correlated with body mass index, waist circumference and waist to hip ratio. Visfatin levels were significantly lower in patients with MS compared to controls (log visfatin: 1.74 ± 0.27 vs. 1.86 ± 0.13 ng/ml, MS vs. control group respectively). We cannot find any significant correlation between visfatin, CRP and IL-6. Also there were no correlation between visfatin levels and any anthropometric parameters in patients with MS or control groups.

Conclusion

Serum visfatin was lower in patients with MS. Therefore it seems that visfatin could not be considered as a pro inflammatory adipocytokine in MS. The positive associations of obesity and visceral adiposity with elevated CRP and IL-6 levels suggest the importance of reducing visceral adiposity to prevent the risk of coronary disease.

Keywords

Metabolic syndrome Visceral adiposity Visfatin IL-6 CRP 

Abbreviations

BMI

Body mass index

BP

Blood pressure

CHD

Coronary heart disease

CRP

C-reactive protein

CVD

Cardiovascular diseases

ELISA

Enzyme-linked immunosorbent assay

EIA

Enzyme immunoassay

FPG

Fasting plasma glucose

Hs-CRP

High-sensitivity C-reactive protein

IL-6

Interleukin 6

IDF

International diabetes federation

MS

Metabolic syndrome

TG

Triglyceride

TNF-α

Tumor necrosis factor-alpha

TLGS

Tehran lipid and glucose study

WHR

Waist to hip ratio

WC

Waist circumference

Notes

Acknowledgments

We thank all persons who participated in this study. We also thank Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences for this collaboration within the framework of the Tehran lipid and glucose study (TLGS). This piece of research was granted by Tehran University of Medical Sciences, Tehran, Iran (grant number: 6068).

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

The study was approved by the ethics committee of Shahid Beheshti University of Medical Sciences.

Informed consent

Written informed consent was obtained from all subjects.

References

  1. 1.
    Lorenzo C, Williams K, Hunt KJ, Haffner SM (2007) The national cholesterol education program-adult treatment panel III, International Diabetes Federation, and World Health Organization definitions of the metabolic syndrome as predictors of incident cardiovascular disease and diabetes. Diabetes Care 30(1):8CrossRefPubMedGoogle Scholar
  2. 2.
    Alberti KG, Zimmet P, Shaw J (2005) The metabolic syndrome—a new worldwide definition. Lancet 366(9491):1059CrossRefPubMedGoogle Scholar
  3. 3.
    Zimmet P, Magliano D, Matsuzawa Y, Alberti G, Shaw J (2005) The metabolic syndrome: a global public health problem and a new definition. Vascular 7:8Google Scholar
  4. 4.
    Maury E, Brichard S (2010) Adipokine dysregulation, adipose tissue inflammation and metabolic syndrome. Mol Cell Endocrinol 314(1):1–16CrossRefPubMedGoogle Scholar
  5. 5.
    Lemieux I, Pascot A, Couillard C, Lamarche B, Tchernof A, Alméras N et al (2000) Hypertriglyceridemic waist: a marker of the atherogenic metabolic triad (hyperinsulinemia; hyperapolipoprotein B; small, dense LDL) in men? Circulation 102(2):179–184CrossRefPubMedGoogle Scholar
  6. 6.
    Carr DB, Utzschneider KM, Hull RL, Kodama K, Retzlaff BM, Brunzell JD et al (2004) Intra-abdominal fat is a major determinant of the national cholesterol education program adult treatment panel III criteria for the metabolic syndrome. Diabetes 53(8):2087–2094CrossRefPubMedGoogle Scholar
  7. 7.
    Reaven GM (1988) Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 37(12):1595CrossRefPubMedGoogle Scholar
  8. 8.
    Koh KK, Han SH, Quon MJ (2005) Inflammatory markers and the metabolic syndrome: insights from therapeutic interventions. J Am Coll Cardiol 46(11):1978–1985CrossRefPubMedGoogle Scholar
  9. 9.
    Shoelson SE, Lee J, Goldfine AB (2006) Inflammation and insulin resistance. J Clin Invest 116(7):1793CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Juge-Aubry CE, Henrichot E, Meier CA (2005) Adipose tissue: a regulator of inflammation. Best Pract Res Clin Endocrinol Metab 19(4):547–566CrossRefPubMedGoogle Scholar
  11. 11.
    Rifai N, Ridker PM (2001) High-sensitivity C-reactive protein: a novel and promising marker of coronary heart disease. Clin Chem 47(3):403PubMedGoogle Scholar
  12. 12.
    Ridker PM, Rifai N, Rose L, Buring JE, Cook NR (2002) Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 347(20):1557–1565CrossRefPubMedGoogle Scholar
  13. 13.
    Devaraj S, Singh U, Jialal I (2009) Human C-reactive protein and the metabolic syndrome. Curr Opin Lipidol 20(3):182CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Yudkin JS, Stehouwer CDA, Emeis JJ, Coppack SW (1999) C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? Arterioscler Thromb Vasc Biol 19(4):972–978CrossRefPubMedGoogle Scholar
  15. 15.
    Bastard JP, Jardel C, Delattre J, Hainque B, Bruckert E, Oberlin F (1999) Evidence for a link between adipose tissue interleukin-6 content and serum C-reactive protein concentrations in obese subjects. Circulation 99(16):2219–2222CrossRefGoogle Scholar
  16. 16.
    Ognjanovic S, Bao S, Yamamoto S, Garibay-Tupas J, Samal B, Bryant-Greenwood G (2001) Genomic organization of the gene coding for human pre-B-cell colony enhancing factor and expression in human fetal membranes. J Mol Endocrinol 26(2):107–117CrossRefPubMedGoogle Scholar
  17. 17.
    Kralisch S, Klein J, Lossner U, Bluher M, Paschke R, Stumvoll M et al (2005) Interleukin-6 is a negative regulator of visfatin gene expression in 3T3-L1 adipocytes. Am J Physiol Endocrinol Metab 289(4):E586–E590CrossRefPubMedGoogle Scholar
  18. 18.
    Kralisch S, Klein J, Lossner U, Bluher M, Paschke R, Stumvoll M et al (2005) Hormonal regulation of the novel adipocytokine visfatin in 3T3-L1 adipocytes. J Endocrinol 185(3):R1CrossRefPubMedGoogle Scholar
  19. 19.
    Ahima RS (2006) Adipose tissue as an endocrine organ. Obesity 14:242S–249SCrossRefPubMedGoogle Scholar
  20. 20.
    Fukuhara A, Matsuda M, Nishizawa M, Segawa K, Tanaka M, Kishimoto K et al (2005) Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 307(5708):426CrossRefPubMedGoogle Scholar
  21. 21.
    Pagano C, Pilon C, Olivieri M, Mason P, Fabris R, Serra R et al (2006) Reduced plasma visfatin/pre-B cell colony-enhancing factor in obesity is not related to insulin resistance in humans. J Clin Endocrinol Metab 91(8):3165CrossRefPubMedGoogle Scholar
  22. 22.
    Haider DG, Schindler K, Schaller G, Prager G, Wolzt M, Ludvik B (2006) Increased plasma visfatin concentrations in morbidly obese subjects are reduced after gastric banding. J Clin Endocrinol Metab 91(4):1578CrossRefPubMedGoogle Scholar
  23. 23.
    Sandeep S, Velmurugan K, Deepa R, Mohan V (2007) Serum visfatin in relation to visceral fat, obesity, and type 2 diabetes mellitus in Asian Indians. Metabolism 56(4):565–570CrossRefPubMedGoogle Scholar
  24. 24.
    Berndt J, Klöting N, Kralisch S, Kovacs P, Fasshauer M, Schön MR et al (2005) Plasma visfatin concentrations and fat depot–specific mRNA expression in humans. Diabetes 54(10):2911CrossRefPubMedGoogle Scholar
  25. 25.
    Zahorska-Markiewicz B, Olszanecka-Glinianowicz M, Janowska J, Kocelak P, Semik-Grabarczyk E, Holecki M et al (2007) Serum concentration of visfatin in obese women. Metabolism 56(8):1131–1134CrossRefPubMedGoogle Scholar
  26. 26.
    Jin H, Jiang B, Tang J, Lu W, Wang W, Zhou L et al (2008) Serum visfatin concentrations in obese adolescents and its correlation with age and high-density lipoprotein cholesterol. Diabetes Res Clin Pract 79(3):412–418CrossRefPubMedGoogle Scholar
  27. 27.
    Davutoglu M, Ozkaya M, Guler E, Garipardic M, Gursoy H, Karabiber H et al (2009) Plasma visfatin concentrations in childhood obesity: relationships with insulin resistance and anthropometric indices. Swiss Med Wkly 139(1–2):22–27PubMedGoogle Scholar
  28. 28.
    Revollo JR, Körner A, Mills KF, Satoh A, Wang T, Garten A et al (2007) Nampt/PBEF/visfatin regulates insulin secretion in [beta] cells as a systemic NAD biosynthetic enzyme. Cell Metab 6(5):363–375CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Saddi-Rosa P, Oliveira CSV, Giuffrida FMA, Reis AF (2010) Visfatin, glucose metabolism and vascular disease: a review of evidence. Diabetol Metab Syndr 2(1):1–6CrossRefGoogle Scholar
  30. 30.
    Azizi F, Rahmani M, Emami H, Mirmiran P, Hajipour R, Madjid M et al (2002) Cardiovascular risk factors in an Iranian urban population: Tehran lipid and glucose study (phase 1). Soz Praventivmed 47(6):408–426CrossRefPubMedGoogle Scholar
  31. 31.
    Azizi F, Ghanbarian A, Momenan AA, Hadaegh F, Mirmiran P, Hedayati M et al (2009) Prevention of non-communicable disease in a population in nutrition transition: Tehran lipid and glucose study phase II. Trials 10(5):19166627Google Scholar
  32. 32.
    Seo JA, Jang ES, Kim BG, Ryu OH, Kim HY, Lee KW et al (2008) Plasma visfatin levels are positively associated with circulating interleukin-6 in apparently healthy Korean women. Diabetes Res Clin Pract 79(1):108–111CrossRefPubMedGoogle Scholar
  33. 33.
    Kim JH, Kim SH, Im JA, Lee DC (2010) The relationship between visfatin and metabolic syndrome in postmenopausal women. Maturitas 67(1):67–71CrossRefPubMedGoogle Scholar
  34. 34.
    Zhong M, Tan H, Gong H, Wang S, Zhang Y, Zhang W (2008) Increased serum visfatin in patients with metabolic syndrome and carotid atherosclerosis. Clin Endocrinol 69(6):878–884CrossRefGoogle Scholar
  35. 35.
    Filippatos T, Derdemezis C, Gazi I, Lagos K, Kiortsis D, Tselepis A et al (2008) Increased plasma visfatin levels in subjects with the metabolic syndrome. Eur J Clin Invest 38(1):71–72CrossRefPubMedGoogle Scholar
  36. 36.
    Lin CC, Lai MM, Li TC, Li CI, Liu CS, Chen CC et al (2009) Relationship between serum retinol-binding protein 4 and visfatin and the metabolic syndrome. Diabetes Res Clin Pract 85(1):24–29CrossRefPubMedGoogle Scholar
  37. 37.
    Olszanecka-Glinianowicz M, Kocełak P, Janowska J, Skorupa A, Nylec M, Zahorska-Markiewicz B (2011) Plasma visfatin and tumor necrosis factor-alpha (TNF-a) levels in metabolic syndrome. Kardiol Polska 69(8):802PubMedGoogle Scholar
  38. 38.
    Chen CC, Li TC, Li CI, Liu CS, Lin WY, Wu MT et al (2007) The relationship between visfatin levels and anthropometric and metabolic parameters: association with cholesterol levels in women. Metabolism 56(9):1216–1220CrossRefPubMedGoogle Scholar
  39. 39.
    Wen Y, Wang H, Wu J, Lu H, Hu XF, Cianflone K (2006) Effects of fatty acid regulation on visfatin gene expression in adipocytes. Chin Med J (Engl) 119(20):1701Google Scholar
  40. 40.
    MacLaren R, Cui W, Cianflone K (2007) Visfatin expression is hormonally regulated by metabolic and sex hormones in 3T3-L1 pre-adipocytes and adipocytes. Diabetes Obes Metab 9(4):490–497CrossRefPubMedGoogle Scholar
  41. 41.
    Nüsken KD, Niisken E, Petrasch M, Rauh M, Dötsch J (2007) Preanalytical influences on the measurement of visfatin by enzyme immuno assay. Clin Chim Acta 382(1–2):154–156CrossRefPubMedGoogle Scholar
  42. 42.
    Körner A, Garten A, Blüher M, Tauscher R, Kratzsch J, Kiess W (2007) Molecular characteristics of serum visfatin and differential detection by immunoassays. J Clin Endocrinol Metab 92(12):4783–4791CrossRefPubMedGoogle Scholar
  43. 43.
    Mohamed-Ali V, Pinkney J, Coppack S (1998) Adipose tissue as an endocrine and paracrine organ. Int J Obes 22:1145–1158CrossRefGoogle Scholar
  44. 44.
    Pickup J, Mattock M, Chusney G, Burt D (1997) NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome X. Diabetologia 40(11):1286–1292CrossRefPubMedGoogle Scholar
  45. 45.
    Yudkin JS, Kumari M, Humphries SE, Mohamed-Ali V (2000) Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link? Atherosclerosis 148(2):209–214CrossRefPubMedGoogle Scholar
  46. 46.
    Florez H, Castillo-Florez S, Mendez A, Casanova-Romero P, Larreal-Urdaneta C, Lee D et al (2006) C-reactive protein is elevated in obese patients with the metabolic syndrome. Diabetes Res Clin Pract 71(1):92–100CrossRefPubMedGoogle Scholar
  47. 47.
    Lyon CJ, Law RE, Hsueh WA (2003) Minireview: adiposity, inflammation, and atherogenesis. Endocrinology 144(6):2195–2200CrossRefPubMedGoogle Scholar
  48. 48.
    Matsuzawa Y, Funahashi T, Nakamura T (1999) Molecular mechanism of metabolic syndrome x: contribution of adipocytokines· adipocyte-derived bioactive substances. Ann N Y Acad Sci 892(1):146–154CrossRefPubMedGoogle Scholar
  49. 49.
    Clement K, Viguerie N, Poitou C, Carette C, Pelloux V, Curat CA et al (2004) Weight loss regulates inflammation-related genes in white adipose tissue of obese subjects. FASEB J 18(14):1657–1669CrossRefPubMedGoogle Scholar
  50. 50.
    Dandona P, Aljada A, Bandyopadhyay A (2004) Inflammation: the link between insulin resistance, obesity and diabetes. Trends Immunol 25(1):4–7CrossRefPubMedGoogle Scholar
  51. 51.
    Fernández-Real JM, Ricart W (2003) Insulin resistance and chronic cardiovascular inflammatory syndrome. Endocr Rev 24(3):278–301CrossRefPubMedGoogle Scholar
  52. 52.
    Arnaud C, Burger F, Steffens S, Veillard NR, Nguyen TH, Trono D et al (2005) Statins reduce interleukin-6-induced C-reactive protein in human hepatocytes. Arterioscler Thromb Vasc Biol 25(6):1231–1236CrossRefPubMedGoogle Scholar

Copyright information

© Italian Society of Endocrinology (SIE) 2016

Authors and Affiliations

  • M. J. Hosseinzadeh-Attar
    • 1
    Email author
  • A. Golpaie
    • 2
  • M. Foroughi
    • 2
  • F. Hosseinpanah
    • 3
  • S. Zahediasl
    • 4
  • F. Azizi
    • 5
  1. 1.Department of Clinical Nutrition, School of Nutritional Sciences and DieteticsTehran University of Medical SciencesTehranIran
  2. 2.Department of Nutrition and Biochemistry, School of Public HealthTehran University of Medical SciencesTehranIran
  3. 3.Obesity Research Center, Research Institute for Endocrine SciencesShahid Beheshti University of Medical SciencesTehranIran
  4. 4.Endocrine Research Center, Research Institute for Endocrine SciencesShahid Beheshti University of Medical SciencesTehranIran
  5. 5.Obesity Research Center and Endocrine Research Center, Research Institute for Endocrine SciencesShahid Beheshti University of Medical ScienceTehranIran

Personalised recommendations